Table 1 Demographic, clinical and laboratory characteristics of the study cohorts
Patient | Cohort I (n = 6) | Cohort II (n = 8) Active disease, systemic | Cohort II (n = 5) Active disease, polyarticular | Cohort II (n = 8) Inactive disease |
|---|---|---|---|---|
Gender | 5 male, 1 female | 5 male, 3 female | 2 male, 3 female | 5 male, 3 female |
Age at diagnosis, years (median, range) | 5.3 (1.8–12.9) | 6.8 (0.4–17.4) | 6.0 (0.5–15.3) | 3.5 (0.4–9.7) |
Time since first symptoms (median, range) | 71 days (47–107 days) | 18.6 months (1.6–109.7 months) | 86.9 months (7.4–198.3 months) | 105.1 months (52.6–195.8 months) |
Number of active joints (median, range) | 2 (1–18) | 3.5 (0–10) | 3 (2–4) | 0 (0–0) |
Platelet count (median, range) | 520,500/mm3 (474,000–557,000/mm3) | 352,000/mm3 (151,000–649,000/mm3) | 276,000/mm3 (195,000–395,000/mm3) | 306,500/mm3 (208,000–394,000/mm3) |
Rheumatoid factor, negative | 6/6 (100%) | 8/8 (100%) | 5/5 (100%) | 8/8 (100%) |
Ferritin, μg/l (median, range) | 414 (32–1785 ) | 754 (234–9980 μg/l) | n.d. | n.d. |
C-reactive protein, mg/dl (median, range) | 11.84 (4.87–25.6) | 3.65 (1.10–26.4) | 0.07 (0.03–6.57) | 0.11 (0.03–0.63) |
Initial prednisolone dose, mg/kg (median, range) | 1.6 (0–2.08) | n.a. | n.a. | n.a. |
Initial anakinra dose, mg/kg (median, range) | 1.63 (1.02–2.5) | n.a. | n.a. | n.a. |